Engineering a potent and long-acting GLP-1/Y<sub>2</sub> receptor dual agonist as a multi-agonist therapy for diabetes and obesity.
為糖尿病和肥胖症工程一種強效且長效的 GLP-1/Y<sub>2</sub> 受體雙激動劑,作為多激動劑治療的一部分。
Peptides 2023-10-11
Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists.
開發一種新型Fc融合蛋白,具有雙重葡萄糖樣肽-1和胃抑制性多肽受體激動劑。
Diabetes Obes Metab 2023-10-11
Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor.
將脂肪酸鏈修飾引入以延長循環半衰期,以應用於葡萄糖依賴性胰島素增生多肽受體的放射配體。
Nucl Med Biol 2024-02-26
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
一種與 GLP-1 類似物結合的 GIPR 拮抗劑,在臨床前和第一階段試驗中促進減重並改善代謝參數。
Nat Metab 2024-02-29
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.
一種GLP-1R/GIPR共激動劑肽的不平衡形式,具有特定位置的N端PEG化,以最大化代謝益處。
iScience 2024-03-22
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Fc融合蛋白胰高血糖素樣肽-1和胰高血糖素雙受體激動劑對不同受體選擇性的體內研究效應。
Biomed Pharmacother 2024-05-10
Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties.
機器學習引導的肽藥物發現:開發具有改善藥物特性的GLP-1受體激動劑。
J Med Chem 2024-07-08